Key barriers include: High costs and insurer risk: Annual prices exceed $5,000 per patient (e.g., Wegovy at ~$450/month), straining small group plans where premiums could rise 10-20% with broad adoption
dorsalis , the total proteins from 100 nonviruliferous, viruliferous, or dsRNAs treated intact insects were extracted and detected by western blot assay with Pns11-, P8-, Pelo-, Hbs1-, E3-, Hsp70-, or H3 IgG as the primary antibody and goat anti-rabbit IgG-peroxidase (Invitrogen, 32460) or goat anti-mouse IgG-peroxidase (Invitrogen, 32430) as the secondary antibody
Provider Comparisons The GLP-1 space is evolving fast
The GLP-1 versus Ozempic comparison explores these differences further
J., & Eisenberg, C
You cannot simply pick up where you left off